GSA Seeks Input on Acquisition Regulations, Including the Alphabet Soup of TDR, PRC, and CSP
Client Alert | 1 min read | 05.30.17
In accordance with President Trump’s continuing mandate to streamline federal regulations, GSA is seeking input on its acquisition regulations, policies, and guidance that may be appropriate for repeal, replacement, or modification. GSA is particularly interested in comments on less frequently addressed areas such as evergreen contracting, price adjustments, catalogs, utilities, construction, and facilities. However, GSA is also welcoming comments on bigger ticket items such as the recent Transactional Data Reporting (TDR) rule, the Price Reduction Clause (PRC), and the Commercial Sales Practice (CSP) format. Comments are due in late July, and will provide interested parties an invaluable opportunity to address a broad swath of GSA’s existing policies and practices. Indeed, with recent indications that compliance with TDR requirements may soon become optional, this request for input appears very well timed to assist GSA in making important decisions for the Schedule program going forward.
Contacts
Insights
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
The U.S. Government Accountability Office’s (GAO) recent decision in Viderity Inc.—Costs, B-424422.5, Sept. 1, 2026, offers useful insight into what constitutes a legally sufficient conflict of interest investigation. The decision arose in an unusual procedural posture: Viderity initially protested, alleging that an agency evaluator had a personal conflict of interest. After the agency took corrective action, Viderity filed a cost entitlement claim requesting that GAO direct the agency to reimburse Viderity’s protest costs. In evaluating that claim, GAO assessed whether Viderity’s underlying protest ground was “clearly meritorious.”
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance



